ElectroCore Inc

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ElectroCore reports record revenue growth and strategic expansion plans

ElectroCore's Q1 2024 earnings call showcased impressive revenue growth, strong gross margins, and successful product launches, underlining the company's market resilience and innovation capabilities. With a focus on strategic expansion and profitability, ElectroCore is well-positioned for sustained growth and market leadership.
While facing challenges in managing R&D expenses and optimizing product returns, ElectroCore's commitment to operational efficiency and market diversification mitigates potential risks. The company's emphasis on employee contributions and customer relationships reinforces its competitive edge and customer loyalty.
By capitalizing on opportunities to expand product offerings, enter new markets, and drive innovation, ElectroCore can unlock significant growth potential and solidify its position as a key player in the neuromodulation industry. Navigating challenges through strategic decision-making and market differentiation will be crucial for ElectroCore's future success.

ElectroCore reports record revenue and margin growth in Q2 2024

ElectroCore's Q2 2024 earnings call showcased exceptional financial performance, marked by record revenue, improved margins, and a notable reduction in net loss.
The company's strengths lie in its revenue growth, product innovation, and solid financial position, while facing challenges in certain product sales and market competition.
Opportunities for ElectroCore include expanding product reach, exploring new therapeutic areas, and leveraging its strong cash position for strategic investments and growth.
Overall, ElectroCore's performance reflects resilience and potential for sustained growth in the healthcare industry, supported by a strong financial foundation and innovative product pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

electroCore: Promising Product Means New Management Team Can Complete Unlikely Turnaround

electroCore, Inc. (ECOR) CEO Dan Goldberger on Q1 2020 Results - Earnings Call Transcript

Generated first quarter revenue of $734,000

electroCore Announces First Quarter Financial Results

Western Asset Global High Income Fund

OPKO Health

Pioneer Floating Rate Trust

Ryman Hospitality Properties

SunPower

Spirit Realty Capital

JPMorgan Chase & Co

1347 Property Insurance Hlds

Daily Insider Ratings Round Up 4/16/20

BASKING RIDGE, N.J., April  17, 2020  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020.

electroCore Provides Business Update and Select First Quarter 2020 Guidance

ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K.

ElectroCore, Inc (NASDAQ: ECOR) shares are trading higher on Friday, after the company announced it has submitted an emergency use authorization application to the FDA to allow the study and use of gammaCore nvVNS therapy to treat respiratory symptoms associated with the coronavirus.

Why ElectroCore's Stock Is Trading Higher Today

Aytu BioScience

CytomX Therapeutics

DHT Holdings

Top Ranked Momentum Stocks to Buy for April 3rd

BASKING RIDGE, N.J., April  02, 2020  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate the study and clinical use of its gammaCore SapphireTM non-invasive vagus nerve stimulation therapy, or nVNS, for respiratory symptoms associated with COVID-19.

electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19

Approval makes novel non-invasive vagus nerve stimulation therapy available for prevention as well as acute treatment of migraines in adults Approval makes novel non-invasive vagus nerve stimulation therapy available for prevention as well as acute treatment of migraines in adults

electroCore Announces 510(k) Clearance of gammaCore™ Label Expansion into Migraine Prevention

BASKING RIDGE, N.J., March  27, 2020  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor.

electroCore Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

electroCore, Inc. (ECOR) CEO Dan Goldberger on Q4 2019 Results - Earnings Call Transcript

Agreement opens reimbursement pathway for thousands of patients with migraine and cluster headache Agreement opens reimbursement pathway for thousands of patients with migraine and cluster headache

electroCore, Inc. Announces Rebate Agreement with Ascent Health Services for gammaCore Preferred Brand Coverage on all Express Scripts Standard National Formularies

BASKING RIDGE, N.J., Dec.  27, 2019  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox, will resign from the Board effective March 31, 2020. Ms. Cox also served on electroCore’s Audit and Nominating and Governance Committees. Michael Atieh, who joined the company’s Board in June 2018, will assume the role of Chairman.

electroCore Announces Board of Directors Transition

NICE has today published a medical technologies guidance document recommending the use of gammaCore within the NHS for the acute and preventive treatment of cluster headache in the U.K. NICE has today published a medical technologies guidance document recommending the use of gammaCore within the NHS for the acute and preventive treatment of cluster headache in the U.K.

NICE Recommends the Use of gammaCore for the Treatment of Cluster Headache in the NHS

BASKING RIDGE, N.J., Nov.  26, 2019  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, Chief Executive Officer, will present  a corporate overview and host investor meetings at the Evercore ISI HealthCONx  Conference 2019, taking place December 2-4, 2019 at Four Seasons Hotel in Boston, Massachusetts, and the LD Micro 12th Annual Main Event conference, taking place December 10-12, 2019 at the Luxe Sunset in Bel-Air, California. 

electroCore to Present at the Two December Investor Conferences

electroCore's (ECOR) CEO Dan Goldberger on Q3 2019 Results - Earnings Call Transcript

BASKING RIDGE, N.J., Sept.  30, 2019  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as Chief Executive Officer, effective October 1. Mr. Goldberger brings to electroCore more than 35 years of experience in the biotechnology and medical technology industries. His areas of expertise include turnarounds, commercial execution, capital formation and product development, among others.

electroCore Appoints Medical Technology Veteran Daniel S. Goldberger as  Chief Executive Officer

As of late, it has definitely been a great time to be an investor in electroCore, Inc. (ECOR).

electroCore, Inc. (ECOR) Shares March Higher, Can It Continue?

electroCore, Inc. (ECOR) CEO Frank Amato on Q2 2019 Results - Earnings Call Transcript

electroCore, Inc. (ECOR) CEO Frank Amato on Q1 2019 Results - Earnings Call Transcript

electroCore, Inc. (ECOR) CEO Frank Amato on Q4 2018 Results - Earnings Call Transcript

Diffusion Pharmaceuticals

Spherix

Year to date, the market has gifted investors a 9.92% return, but it remains off 5.73% from the start of the fourth quarter. While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been active.

News for ElectroCore Inc Stock (ECOR)